Marla C Dubinsky, MD
-
- Positions
- PROFESSOR | Pediatrics, Gastroenterology
- PROFESSOR | Medicine, Gastroenterology
-
- Specialties
- Pediatrics
- Pediatric Gastroenterology
-
- Language
- English
-
- Hospital Affiliations
- Mount Sinai Morningside and Mount Sinai West
- Mount Sinai Queens
- Mount Sinai Beth Israel
- The Mount Sinai Hospital
-
- Phone
- 212-241-5415 212-241-5415
-
The Susan & Leonard Feinstein IBD Clinical Center
17 East 102nd Street, 5th Floor East
New York, NY 10029
Phone: 212-241-5415212-241-5415
Dr. Dubinsky received her medical degree from Queen’s University, Canada. She completed her Pediatric Residency at Alberta Children’s Hospital, Calgary, Canada and her Clinical Fellowship in Gastroenterology and Nutrition at Sainte-Justine Hospital at the University of Montreal, Canada. She then completed her Research Fellowship in Inflammatory Bowel Disease at Cedars-Sinai Medical Center in Los Angeles where she then served as the Director of the Pediatric Inflammatory Bowel Disease Center before coming to Mount Sinai as the Chief of the Division of Pediatric Gastroenterology at the Mount Sinai Kravis Children's Hospital. She is also the Co-Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at Mount Sinai. Her primary research focuses on the influence of genetics and immune responses on the variability in clinical presentations, treatment responses and prognosis of early-onset IBD. Her other interests include the impact of IBD on fertility and pregnancy. She has lectured widely both nationally and internationally and has published in 160 peer reviewed journals including Lancet, Gastroenterology, The Journal of Pediatric Gastroenterology and Nutrition, Inflammatory Bowel Diseases, and the American Journal of Gastroenterology. She also currently sits on the editorial boards of several leading journals.
Mount Sinai Health System’s Marla C. Dubinsky, MD, and Laurie A. Keefer, PhD, are co-founders of Trellus Health, which has entered into an exclusive multi-year contract with Mount Sinai to commercialize a patent-pending GRITT-IBD™ resilience assessment and personalized integrated care pathways. Read about "The Science of Resilience Meets Technology" in the 2021 Mount Sinai Kravis Children's Hospital Pediatric Report.
Certification
Pediatric Gastroenterology
Clinical Focus
- Colonoscopy
- Crohn's Disease
- Gastroenterology
- Inflammatory Bowel Disease
- Ulcerative Colitis
- Upper GI Endoscopy
Research Topics
Inflammatory Bowel Disease (IBD), Personalized Medicine, Pharmacogenomics
Education
MD, Queen's University
Residency, Pediatrics
Alberta Children's Hospital
Fellowship, Pediatric Gastroenterology
CHU Sainte-Justine (St. Justine Hospital)
Language
English
2010
International Organization for the Study of Inflammatory Bowel Disease
2009
Abe and Claire Levine Chair in Pediatric Inflammatory Bowel Disease
2008
Lectureship Award, University of Calgary
2007
Corrine and Lenny Sands Clinical Investigator Award
Dr. Dubinsky's research interests include:
- Microbiome and genetics
- Pharmacogenetics
- Pregnancy, preconception, and fertility
- Prognostic models
- Therapeutic drug monitoring
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Dubinsky during 2020 and/or 2021. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Company Founder:
- Cornerstones Health Inc.
Consulting:
- AbbVie Inc.
- Arena
- Bristol-Myers Squibb
- Celgene Corporation
- Cornerstones Health Inc.
- Eli Lilly and Company
- Genentech, Inc.
- Gilead Sciences, Inc.
- Janssen Biotech, Inc., formerly Centocor Biotech, Inc.
- Pfizer Inc.
- Prometheus Laboratories Inc.
- ReveraGen Biopharma
- Takeda Pharmaceutical Company Limited
- UCB S.A.
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- GoDuRun llc
- MiTest Health
- Trellus Health
Scientific Advisory Board:
- AbbVie Inc.
- Arena
- Celgene Corporation
- Eli Lilly and Company
- Genentech, Inc.
- Janssen Biotech, Inc., formerly Centocor Biotech, Inc.
- Pfizer Inc.
- Prometheus Laboratories Inc.
- Salix Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.